



March 10, 2022

The Manager- Listing
BSE Limited
(BSE: 507685)

The Manager- Listing
National Stock Exchange of India Limited,
(NSE: WIPRO)

The Market Operations,
NYSE: New York
(NYSE: WIT)

Dear Sir/Madam,

Sub: Press Release

Please find attached herewith copy of the Press Release which is being released today.

Thanking you,

For Wipro Limited

G Kothandaraman
General Manager- Finance

Registered Office:

Wipro Limited T : +91 (80) 2844 0011
Doddakannelli F : +91 (80) 2844 0054
Sarjapur Road E : info@wipro.com
Bengaluru 560 035 W : wipro.com
India C : L32102KA1945PLC020800





Wipro and Pandorum Partner to Accelerate Regenerative Medicine with AI

Use of Wipro Holmes Artificial Intelligence capabilities will lead to faster development of advanced therapeutics, improving patient outcomes

New York, USA and Bangalore, India – March 10, 2022: Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting, and business process services company, and Pandorum Technologies, a biotechnology company working in the field of tissue engineering and regenerative medicine, today announced a long-term partnership. Together, the companies will focus on development of technologies that shorten time-to-market and maximize patient outcome during R&D and clinical trials of regenerative medicine. The partnership combines the Artificial Intelligence (AI) capabilities of Wipro Holmes with Pandorum's expertise in regenerative medicine.

The initial focus of collaboration will be on 'bio-engineered liquid cornea' and will expand across the product pipeline including lung and liver regenerative tissues.

Wipro Holmes AI-based decision support solution will provide insights on the potential outcomes of specific formulations, apply advanced algorithms to predict and improve the efficacy of therapeutics, and help in clinical study design.

The combined vision of Pandorum and Wipro is to build an AI system that learns from the multi-dimensional data coming out of Pandorum's R&D pipeline at the cellular, tissue (organoid) and organ levels, and provides actionable insights. Wipro Holmes' capability in deriving insights from phenotypes, genotypes and clinical progression assessments will complement Pandorum's state-of-the-art capabilities in tissue regeneration and regenerative medicine. Pandorum is on the cusp of entering clinical stage, and the exponential partnership with Wipro, merging Pandorum's expertise and artificial intelligence, will unlock the power of regenerative medicine.

"By embracing digital technologies such as artificial intelligence, life sciences organizations can accelerate innovation, transform business processes and fuel growth. In life sciences R&D, AI is particularly valuable to rapidly discover new formulations, expedite therapeutic development and bring life-saving therapies to market faster, thereby positively influencing human health. With our domain and AI expertise, we stand ready to enable our health and life sciences clients to serve their stakeholders better," said **Rajan Kohli, President and Managing Partner, iDEAS, Wipro Limited.**

"We're living in a time of unprecedented progress in biology, data science and machine learning. We are building a framework to converge these three fields, in order to harness the potential of tissue reprogramming to the fullest and address global unmet clinical needs, such as, corneal blindness, Liver diseases. In the end, what matters most is to be able to alleviate the suffering of the patients. Together with Wipro, we hope to accelerate this process" said **Tuhin Bhowmick, Co-founder & Chief Executive Officer, Pandorum.**

“Regenerative medicine is an alternative option for many patients awaiting donors for transplant. We are excited to bring Wipro Holmes advanced AI capabilities to Pandorum, which will accelerate the development of successful regenerative therapeutics and enable better outcomes for the patients. Our focus on developing explainable AI and built-in capabilities for data privacy makes Wipro Holmes the most suitable for life sciences R&D and clinical trials,” said **Harmeet Chauhan, Global Head - Engineering and R&D, Wipro Limited.**

About Pandorum

Pandorum Technologies Private Limited (India) and its US subsidiary, Pandorum International Inc., together addressed as Pandorum, are developing next-generation therapies in the field of Tissue Engineering and Regenerative Medicine. At Pandorum, we have been using our proprietary technology platforms to develop advanced treatments for the regeneration of various human tissues including cornea, liver, and lung. The clinical translation of Pandorum’s product pipeline is supported by multiple prestigious clinical collaborators in India and the US. Our technology platforms and products are being developed with the aim to extend and improve the quality of millions of lives across the world.

About Wipro Limited

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO) is a leading global information technology, consulting and business process services company. We harness the power of cognitive computing, hyper-automation, robotics, cloud, analytics and emerging technologies to help our clients adapt to the digital world and make them successful. A company recognized globally for its comprehensive portfolio of services, strong commitment to sustainability and good corporate citizenship, we have over 220,000 dedicated employees serving clients across six continents. Together, we discover ideas and connect the dots to build a better and a bold new future.

Media Contact:

Pandorum

contact@pandorumtechnologies.in

Sandeep Deb Varman

Wipro Limited

sandeep.varman@wipro.com

Forward-Looking Statements

The forward-looking statements contained herein represent Wipro’s beliefs regarding future events, many of which are by their nature, inherently uncertain and outside Wipro’s control. Such statements include, but are not limited to, statements regarding Wipro’s growth prospects, its future financial operating results, and its plans, expectations and intentions. Wipro cautions readers that the forward-looking statements contained herein are subject to risks and uncertainties that could cause actual results to differ materially from the results anticipated by such statements. Such risks and uncertainties include, but are not limited to, risks and uncertainties regarding fluctuations in our earnings, revenue and profits, our ability to generate and manage growth, complete proposed corporate actions, intense competition in IT services, our ability to maintain our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which we make strategic investments, withdrawal of fiscal governmental incentives, political instability, war, legal restrictions on raising capital or acquiring companies outside India,

unauthorized use of our intellectual property and general economic conditions affecting our business and industry. The conditions caused by the COVID-19 pandemic could decrease technology spending, adversely affect demand for our products, affect the rate of customer spending and could adversely affect our customers' ability or willingness to purchase our offerings, delay prospective customers' purchasing decisions, adversely impact our ability to provide on-site consulting services and our inability to deliver our customers or delay the provisioning of our offerings, all of which could adversely affect our future sales, operating results and overall financial performance. Our operations may also be negatively affected by a range of external factors related to the COVID-19 pandemic that are not within our control. Additional risks that could affect our future operating results are more fully described in our filings with the United States Securities and Exchange Commission, including, but not limited to, Annual Reports on Form 20-F. These filings are available at www.sec.gov. We may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. We do not undertake to update any forward-looking statement that may be made from time to time by us or on our